| HOME >> BIOLOGY >> TECHNOLOGY |
David Sumner, Medicsight's Chief Executive, said: "Two recent major studies have confirmed that CT colonography is at least as sensitive and accurate as conventional optical colonoscopy as a screening tool for colorectal cancer. These results are the basis for initiatives such as the Cubin bill to introduce routine reimbursement for CT colonography for screening those aged 50 or more who are most at risk of developing this devastating condition. Medicsight's ColonCAD(TM) software, which can be used with any multi-detector CT imaging equipment, helps radiologists to interpret the CT scans and identify early-stage lesions. We expect the Company and its CAD software to be an important beneficiary of this trend."
About MGT Capital Investments, Inc.
MGT Capital Investments, Inc is a holding company that focuses on investments in the global healthcare information technology market. The Company has two subsidiaries, Medicsight PLC and Medicexchange PLC.
Medicsight PLC (traded on the AIM market of the London Stock Exchange, under the Ticker symbol MDST) is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's computer-aided detection (CAD) software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data.
Medicexchange PLC provides medical imaging professionals with a global
web portal containing an online sales, jobs and inf
'/>"/>
| SOURCE MGT Capital Investments, Inc. Copyright©2007 PR Newswire. All rights reserved |